Download PDF
Synlett
DOI: 10.1055/a-2221-9096
letter
Japan/Netherlands Gratama Workshop

Systematic Strategy for the Development of Glycosyltransferase Inhibitors: Diversity-Oriented Synthesis of FUT8 Inhibitors

Yoshiyuki Manabe∗
a   Department of Chemistry, Graduate School of Science, Osaka University, Machikaneyama, Toyonaka, Osaka 560-0043, Japan
b   Forefront Research Center, Osaka University, 1-1 Machikaneyama, Toyonaka, Osaka 560-0043, Japan
,
Koki Hizume
a   Department of Chemistry, Graduate School of Science, Osaka University, Machikaneyama, Toyonaka, Osaka 560-0043, Japan
,
Yohei Takakura
a   Department of Chemistry, Graduate School of Science, Osaka University, Machikaneyama, Toyonaka, Osaka 560-0043, Japan
,
Shinji Takamatsu
c   Department of Molecular Biochemistry and Clinical Investigation, Graduate School of Medicine, Osaka University, 1-7 Yamadaoka, Suita, Osaka 565-0871, Japan
,
Eiji Miyoshi
c   Department of Molecular Biochemistry and Clinical Investigation, Graduate School of Medicine, Osaka University, 1-7 Yamadaoka, Suita, Osaka 565-0871, Japan
,
Yoshihiro Kamada
d   Department of Advanced Metabolic Hepatology, Graduate School of Medicine, Osaka University, 1-7 Yamadaoka, Suita, Osaka 565-0871, Japan
,
Ramón Hurtado-Guerrero
e   Institute of Biocomputation and Physics of Complex Systems (BIFI), University of Zaragoza, Mariano Esquillor s/n, Campus Rio Ebro, Edificio I+D, Zaragoza, Spain
f   Fundación ARAID, 50018, Zaragoza, Spain
g   Copenhagen Center for Glycomics, Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark
,
Koichi Fukase∗
a   Department of Chemistry, Graduate School of Science, Osaka University, Machikaneyama, Toyonaka, Osaka 560-0043, Japan
b   Forefront Research Center, Osaka University, 1-1 Machikaneyama, Toyonaka, Osaka 560-0043, Japan
h   Center for Advanced Modalities and DDS, Osaka University, 1-1 Yamadaoka, Suita, Osaka 565-0871, Japan
› Author AffiliationsThis work was financially supported by JSPS KAKENHI grants 20H05675, 20K05727, 20H04709, 21H05074, and 23K17372, as well as JST CREST grant JPMJCR20R3, AMED grants 20ek0109444h0001, 20fk0210079h0001, and JST FOREST Program grant JPMJFR211Z. R.H-G. acknowledges support from the Agencia Estatal de Investigación (PID2019-105451GB-I00 and PID2022-136362NB-I00).
› Further Information
    Permissions and Reprints All articles of this category


Abstract

Glycans control various biological processes, depending on their structures. Particularly, core fucose, formed by α1,6-fucosyltransferase (FUT8), has a substantial influence on multiple biological processes. In this study, we investigated the development of FUT8 inhibitors with structural elements encompassing both the glycosyl donor (GDP-fucose) and acceptor (N-glycan) of FUT8. To efficiently optimize the structure of FUT8 inhibitors, we employed a strategy involving fragmentation of the target structure, followed by a structure optimization using a diversity-oriented synthesis approach. This study proposes an efficient strategy to accelerate the structural optimization of middle molecules.

Key words

compound libraries - diversity-oriented synthesis - glycosyltransferase - enzyme inhibitor - diversity-oriented synthesis

Supporting Information

    Supporting information for this article is available online at https://doi.org/10.1055/a-2221-9096.
  • Supporting Information


Publication History

Received: 30 October 2023

Accepted after revision: 04 December 2023

Accepted Manuscript online:
04 December 2023

Article published online:
15 January 2024

© 2023. Thieme. All rights reserved

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References and Notes

    • 1a Fuster MM, Esko JD. Nat. Rev. Cancer 2005; 5: 526
      CrossrefPubMed
    • 1b van Kooyk Y, Rabinovich GA. Nat. Immunol. 2008; 9: 593
      CrossrefPubMed
    • 1c Lichtenstein RG, Rabinovich GA. Cell Death Differ. 2013; 20: 976
      CrossrefPubMed
    • 1d Reily C, Stewart TJ, Renfrow MB, Novak J. Nat. Rev. Nephrol. 2019; 15: 346
      CrossrefPubMed
    • 1e Smith BA. H, Bertozzi CR. Nat. Rev. Drug Discovery 2021; 20: 217
      CrossrefPubMed
  • 2 Uozumi N, Yanagidani S, Miyoshi E, Ihara Y, Sakuma T, Gao C.-X, Teshima T, Fujii S, Shiba T, Taniguchi N. J. Biol. Chem. 1996; 271: 27810
    CrossrefPubMed
  • 3 Takahashi M, Kuroki Y, Ohtsubo K, Taniguchi N. Carbohydr. Res. 2009; 344: 1387
    CrossrefPubMed
  • 4 Wang X, Inoue S, Gu J, Miyoshi E, Noda K, Li W, Mizuno-Horikawa Y, Nakano M, Asahi M, Takahashi M, Uozumi N, Ihara S, Lee SH, Ikeda Y, Yamaguchi Y, Aze Y, Tomiyama Y, Fujii J, Suzuki K, Kondo A, Shapiro SD, Lopez-Otin C, Kuwaki T, Okabe M, Honke K, Taniguchi N. Proc. Natl. Acad. Sci. U.S.A. 2005; 102: 15791
    CrossrefPubMed
    • 5a Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, Hanai N, Shitara K. J. Biol. Chem. 2003; 278: 3466
      CrossrefPubMed
    • 5b Shields RL, Lai J, Keck R, O’Connell LY, Hong K, Meng YG, Weikert SH. A, Presta LG. J. Biol. Chem. 2002; 277: 26733
      CrossrefPubMed
    • 5c Satoh M, Shitara K, Hanai N. Trends Glycosci. Glycotechnol. 2006; 18: 129
      Crossref
    • 5d Niwa R, Shoji-Hosaka E, Sakurada M, Shinkawa T, Uchida K, Nakamura K, Matsushima K, Ueda R, Hanai N, Shitara K. Cancer Res. 2004; 64: 2127
      CrossrefPubMed
  • 6 Wang X, Gu J, Ihara H, Miyoshi E, Honke K, Taniguchi N. J. Biol. Chem. 2006; 281: 2572
    CrossrefPubMed
  • 7 Wang X, Fukuda T, Li W, Gao C.-x, Kondo A, Matsumoto A, Miyoshi E, Taniguchi N, Gu J. J. Biochem. 2009; 145: 643
    CrossrefPubMed
    • 8a Bastian K, Scott E, Elliott DJ, Munkley J. Int. J. Mol. Sci. 2021; 22: 455
      CrossrefPubMed
    • 8b Liao C, An J, Yi S, Tan Z, Wang H, Li H, Guan X, Liu J, Wang Q. J. Cancer 2021; 12: 4109
      CrossrefPubMed
  • 9 Miyoshi E, Noda K, Yamaguchi Y, Inoue S, Ikeda Y, Wang W, Ko JH, Uozumi N, Li W, Taniguchi N. Biochim. Biophys. Acta, Gen. Subj. 1999; 1473: 9
    CrossrefPubMed
    • 10a Moriwaki K, Noda K, Furukawa Y, Ohshima K, Uchiyama A, Nakagawa T, Taniguchi N, Daigo Y, Nakamura Y, Hayashi N, Miyoshi E. Gastroenterology 2009; 137: 188
      CrossrefPubMed
    • 10b Tanaka K, Moriwaki K, Yokoi S, Koyama K, Miyoshi E, Fukase K. Bioorg. Med. Chem. 2013; 21: 1074
      CrossrefPubMed
  • 11 Okada M, Chikuma S, Kondo T, Hibino S, Machiyama H, Yokosuka T, Nakano M, Yoshimura A. Cell Rep. 2017; 20: 1017
    CrossrefPubMed
    • 12a Shen N, Lin H, Wu T, Wang D, Wang W, Xie H, Zhang J, Feng Z. Kidney Int. 2013; 84: 64
      CrossrefPubMed
    • 12b Wang N, Deng Y, Liu A, Shen N, Wang W, Du X, Tang Q, Li S, Odeh Z, Wu T, Lin H. Sci. Rep. 2017; 7: 16914
      CrossrefPubMed
  • 13 Gao C, Maeno T, Ota F, Ueno M, Korekane H, Takamatsu S, Shirato K, Matsumoto A, Kobayashi S, Yoshida K, Kitazume S, Ohtsubo K, Betsuyaku T, Taniguchi N. J. Biol. Chem. 2012; 287: 16699
    CrossrefPubMed
    • 15a Tu Z, Lin Y.-N, Lin C.-H. Chem. Soc. Rev. 2013; 42: 4459
      CrossrefPubMed
    • 15b Burkart MD, Vincent SP, Düffels A, Murray BW, Ley SV, Wong C.-H. Bioorg. Med. Chem. 2000; 8: 1937
      CrossrefPubMed
    • 15c Murray BW, Wittmann V, Burkart MD, Hung S.-C, Wong C.-H. Biochemistry 1997; 36: 823
      CrossrefPubMed
    • 15d Luengo JI, Gleason JG. Tetrahedron Lett. 1992; 33: 6911
      Crossref
    • 15e Norris AJ, Whitelegge JP, Strouse MJ, Faull KF, Toyokuni T. Bioorg. Med. Chem. Lett. 2004; 14: 571
      CrossrefPubMed
    • 15f Ichikawa Y, Lin YC, Dumas DP, Shen GJ, Garcia-Junceda E, Williams MA, Bayer R, Ketcham C, Walker LE. J. Am. Chem. Soc. 1992; 114: 9283
      Crossref
    • 15g Qiao L, Murray BW, Shimazaki M, Schultz J, Wong C.-H. J. Am. Chem. Soc. 1996; 118: 7653
      Crossref
    • 15h Wong C.-H, Dumas DP, Ichikawa Y, Koseki K, Danishefsky SJ, Weston BW, Lowe JB. J. Am. Chem. Soc. 1992; 114: 7321
      Crossref
    • 15i Mitchell ML, Tian F, Lee LV, Wong C.-H. Angew. Chem. Int. Ed. 2002; 41: 3041
      CrossrefPubMed
    • 15j Carchon G, Chrétien F, Delannoy P, Verbert A, Chapleur Y. Tetrahedron Lett. 2001; 42: 8821
      Crossref
    • 15k Lee LV, Mitchell ML, Huang S.-J, Fokin VV, Sharpless KB, Wong C.-H. J. Am. Chem. Soc. 2003; 125: 9588
      CrossrefPubMed
    • 15l Manabe Y, Kasahara S, Takakura Y, Yang X, Takamatsu S, Kamada Y, Miyoshi E, Yoshidome D, Fukase K. Bioorg. Med. Chem. 2017; 25: 2844
      CrossrefPubMed
    • 15m Dai Y, Hartke R, Li C, Yang Q, Liu JO, Wang L.-X. ACS Chem. Biol. 2020; 15: 2662
      CrossrefPubMed
    • 16a Okeley NM, Alley SC, Anderson ME, Boursalian TE, Burke PJ, Emmerton KM, Jeffrey SC, Klussman K, Law C.-L, Sussman D, Toki BE, Westendorf L, Zeng W, Zhang X, Benjamin DR, Senter PD. Proc. Natl. Acad. Sci. U.S.A. 2013; 110: 5404
      CrossrefPubMed
    • 16b Rillahan CD, Antonopoulos A, Lefort CT, Sonon R, Azadi P, Ley K, Dell A, Haslam SM, Paulson JC. Nat. Chem. Biol. 2012; 8: 661
      CrossrefPubMed
    • 16c Kizuka Y, Nakano M, Yamaguchi Y, Nakajima K, Oka R, Sato K, Ren C.-T, Hsu T.-L, Wong C.-H, Taniguchi N. Cell Chem. Biol. 2017; 24: 1467
      CrossrefPubMed
  • 17 Wang M, Zhang Z, Chen M, Lv Y, Tian S, Meng F, Zhang Y, Guo X, Chen Y, Yang M, Li J, Qiu T, Xu F, Li Z, Zhang Q, Yang J, Sun J, Zhang H, Zhang H, Li H, Wang W. Cell Death Dis. 2023; 14: 495
    CrossrefPubMed
  • 18 8: EtONa (1.80 mg, 26.4 μmol) was added to a solution of 4 (2.52 mg, 3.30 μmol) in anhyd EtOH (150 μL) at r.t., and the mixture was stirred for 1 d at 60 °C. Anhyd THF (200 μL) and EtONa (1.90 mg, 27.9 μmol) were at r.t., and the resulting mixture was stirred for 1 d at 60 °C. Additional anhyd THF (150 μL) and EtONa (1.50 mg, 22.0 μmol) were then added at r.t., and the mixture was stirred for 1 d at 60 °C. The mixture was neutralized with DOWEX (50W×8 50–100) at r.t. and then filtered. The filtrate was concentrated in vacuo, and the residue was dissolved in 50% TFA–CH2Cl2 (400 μL). The resulting mixture was stirred for 30 min at r.t., then diluted with toluene and azeotroped twice. The residue was purified by reverse-phase HPLC [Cosmosil 5C18-AR-300 4.6 × 250 mm column, 2–24% MeCN–H2O (linear gradient; 33 min) + 0.1% HCOOH, 1.0 mL/min] to give a colorless oil; yield: 0.38 mg (21%). 1H NMR (500 MHz, CD3OD): δ = 8.70 (s, 1 H), 4.60 (q, J = 7.1 Hz, 2 H), 4.26–4.21 (m, 3 H), 4.08 (dt, J = 10.6, 6.0 Hz, 1 H), 3.85 (dt, J = 10.6, 5.9 Hz, 1 H), 3.65–3.59 (m, 2 H), 3.48–3.39 (m, 4 H), 2.61 (t, J = 6.0 Hz, 2 H), 1.98–1.92 (m, 2 H), 1.91–1.84 (m, 2 H), 1.53–1.48 (m, 2 H), 1.46 (t, J = 7.2 Hz, 3 H), 1.25 (d, J = 6.5 Hz, 3 H). HRMS (ESI-Orbitrap): m/z [M – H + 2 Na]+ calcd for C21H33N6Na2O9S: 591.1820; found: 591.1819.
    • 19a Kötzler MP, Blank S, Bantleon FI, Spillner E, Meyer B. Biochim. Biophys. Acta. Gen. Subj. 2012; 1820: 1915
      CrossrefPubMed
    • 19b Kötzler MP, Blank S, Bantleon FI, Wienke M, Spillner E, Meyer B. ACS Chem. Biol. 2013; 8: 1830
      CrossrefPubMed
    • 19c García-García A, Ceballos-Laita L, Serna S, Artschwager R, Reichardt NC, Corzana F, Hurtado-Guerrero R. Nat. Commun. 2020; 11: 973
      CrossrefPubMed
    • 20a Rostovtsev VV, Green LG, Fokin VV, Sharpless KB. Angew. Chem. Int. Ed. 2002; 41: 2596
      CrossrefPubMed
    • 20b Tornøe CW, Christensen C, Meldal M. J. Org. Chem. 2002; 67: 3057
      CrossrefPubMed
  • 21 21: To a solution of 12 (29.4 μg, 0.05 μmol) in DMSO (5 μL), H2O (8 μL) and phosphate-buffered saline (10×PBS; 5 μL) were added 17.0 μL (0.05 μmol) of a solution of 15 (0.17 μmol) in H2O (56.0 μL), 5 μL (0.05 μmol) of a solution of THPTA (4.60 μmol) in H2O (460 μL), 5 μL (0.05 μmol) of a solution of sodium ascorbate (10.1 μmol) in H2O (1 mL), and 5 μL (0.05 μmol) of a solution of CuSO4 (12.5 μmol) in H2O (1.25 mL) at r.t., and the mixture was stirred for 3 h at 37 °C. The resulting mixture was purified by reverse-phase HPLC [Cosmosil 5C18-AR-300 2.0 × 150 mm column, 5–30% MeCN–H2O (linear gradient; 50 min) + 0.1% HCOOH, flow rate 0.2 mL/min] to give a white solid; yield: 31.7 μg [28%, estimated by UV (λ = 280 nm) absorption in HPLC analysis]. HRMS (ESI-Orbitrap): m/z [M – 2 H]2– calcd for C87H139N15O52S: 1128.9213; found; 1128.9220.